BNP Paribas

Aladom is a web portal that connects individuals seeking home services with providers in various fields. Launched in France in 2008, it offers a platform where users can find and hire services across more than 70 categories, including childcare, personal assistance, tutoring, and cleaning. With over 85,000 classified advertisements, Aladom facilitates the recruitment process for both service seekers and providers. The platform expanded its reach in 2011 by entering the German and Belgian markets, followed by a presence in the USA and Spain in 2012. This comprehensive service network allows clients to effectively meet their daily needs through a user-friendly interface.

Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacture of small satellites equipped with advanced sensors. The company focuses on creating satellite imagery technology that captures high-resolution optical data, allowing for frequent data collection. In addition to satellite production, Aerospacelab develops tools that utilize artificial intelligence and machine learning to automate various tasks, facilitating processes such as surveying and monitoring. This innovative approach enables customers to efficiently analyze substantial volumes of data and optimize the extraction of valuable insights from the information gathered.

Eurostar International Limited operates high-speed rail services between London and major European cities, including Paris, Brussels, Lille, Calais, Disneyland Paris, and the French Alps. Founded in 1990 and headquartered in London, Eurostar is a subsidiary of SNCF Mobilités Group. It provides direct connections via the Channel Tunnel, carrying over 150 million passengers since its inception in 1994. The company offers three travel classes, online booking options, and combined train and hotel packages for customers' convenience.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for Alzheimer’s, Parkinson’s, diabetes, and other protein-misfolding disorders. The company is advancing several investigational compounds, including ReS19-T for Alzheimer’s and ReS39 for diabetes, as well as ReS3-T, which targets neuronal hyperactivity associated with Alzheimer’s and epilepsy. Additionally, reMYND operates a phenotypic screening platform aimed at discovering small molecule treatments that mitigate the toxicity of misfolded proteins such as Tau and Synuclein. The company also functions as a contract research organization (CRO), providing services that assess the in-vivo characteristics and effects of experimental therapies using proprietary mouse models. This CRO capability has enabled reMYND to support various pharmaceutical clients, including major companies in the United States, Europe, and Japan, by delivering critical proof-of-concept data for drugs in clinical development. Established in 2002, reMYND is committed to addressing the challenges posed by protein misfolding diseases through innovative research and development.

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for Alzheimer’s, Parkinson’s, diabetes, and other protein-misfolding disorders. The company is advancing several investigational compounds, including ReS19-T for Alzheimer’s and ReS39 for diabetes, as well as ReS3-T, which targets neuronal hyperactivity associated with Alzheimer’s and epilepsy. Additionally, reMYND operates a phenotypic screening platform aimed at discovering small molecule treatments that mitigate the toxicity of misfolded proteins such as Tau and Synuclein. The company also functions as a contract research organization (CRO), providing services that assess the in-vivo characteristics and effects of experimental therapies using proprietary mouse models. This CRO capability has enabled reMYND to support various pharmaceutical clients, including major companies in the United States, Europe, and Japan, by delivering critical proof-of-concept data for drugs in clinical development. Established in 2002, reMYND is committed to addressing the challenges posed by protein misfolding diseases through innovative research and development.

GAMBIT Financial Solutions SA, founded in 2007 and based in Liege, Belgium, specializes in investment advisory and risk management solutions. The company focuses on providing a digital investment platform that combines algorithmic technology with the expertise of investment professionals. Its services include investment profiling, portfolio optimization, and comprehensive risk and compliance management. By translating complex financial concepts into clear and actionable insights, GAMBIT aims to support the financial community with effective business solutions tailored to their needs.

Algonquin SA, founded in 1998 and based in Brussels, Belgium, specializes in the investment, ownership, operation, and franchising of hotels across Europe. The company manages a portfolio of 43 hotel assets, offering over 7,500 rooms with an estimated value of €1.8 billion. Approximately half of these hotels operate under Algonquin's own brands or well-known international franchises, while the remainder is managed through agreements with major international operators. Algonquin distinguishes itself by actively engaging in hotel operations, providing expertise in both daily management tasks and real estate matters. This dual role allows Algonquin to optimize operational efficiency and enhance the value of its properties, making it an attractive partner for institutional investors, family offices, and private equity firms seeking to collaborate in dedicated investment vehicles.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that focuses on inventing and developing small molecule drugs that target G-Protein Coupled Receptors (GPCRs). The company's lead product, fezolinetant, is currently in Phase II clinical development for treating women's health disorders. In addition to fezolinetant, Ogeda is developing other small molecules aimed at addressing various therapeutic areas, including inflammatory and autoimmune diseases. Founded in 1994 and formerly known as Euroscreen, Ogeda operates additional facilities in Brussels, Belgium, and Paris, France. The company is a subsidiary of Astellas Pharma Inc. and is supported by prominent investors in the biotechnology sector.